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Contrast agents for cardiovascular magnetic
resonance imaging: an overview
Marco M. Meloni,*ab Stephen Barton, b Lei Xu,c Juan C. Kaski,a Wenhui Songd
and Taigang He*ae
Cardiovascular Magnetic Resonance (CMR), a non-invasive and nonionizing imaging technique, plays a
major role in research and clinical cardiology. The strength of CMR lies in its high temporal resolution,
superior contrast, and unique tissue characterization capabilities. Contrast agents have been used to
improve sensitivity and specificity of CMR in detecting and evaluating various pathologies. Much eﬀort
has been made to develop more eﬃcient contrast reagents to detect cardiovascular diseases at an
asymptomatic stage, which has led to a plethora of products in animal studies. However, very few of the
developed contrast agents are currently approved for human use. Major obstacles are high dosages, toxicity,
body clearance rate and long-term immunogenicity. In this review, we critically assess recent developments
in the field of the contrast agents for CMR, highlighting both benefits and current drawbacks. A clearer insight
regarding the challenges facing the development of improved contrast agents may help collaborative work to
enhance images contrast, decrease toxicity and accelerate their translation into clinical use.
1. Introduction
Cardiovascular diseases (CVDs) are a group of disorders of the
heart and blood vessels and remain the biggest cause of deaths
worldwide, representing 31% of all deaths.1 Cardiovascular
imaging plays a pivotal role in modern health care and constitutes
an essential component in the management of patients with
cardiovascular conditions. Current imaging modalities for
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assessment of CVDs include ultrasonography, Positron Emission
Tomography (PET), Computed Tomography (CT) and Magnetic
Resonance Imaging (MRI). Since the pioneering work of Lauterbur
and Mansfield in the 1970s,2 MRI has become a staple of imaging
modality in medical science and clinical practice. For the heart and
vascular system, the term CMR is often used. To note, although it is
often routinely used for CVS imaging, CT is an X-ray basedmodality
known for its radiation problems. By contrast, CMR does not use
radiation and has no known side eﬀects. CMR also aﬀords superb
soft tissue contrast, providing a comprehensive assessment of
cardiac morphology, function, perfusion, viability, coronary artery
stenosis and quantitative tissue characterisation.3 In view of these
capabilities, CMR is often known as the ‘‘one-stop shop’’ for
virtually any form of cardiovascular disease.
Because the endogenous diﬀerences between tissues in MRI
can be small, a contrast agent (CA) is often used in MRI to
provide additional contrast to distinguish a target tissue from its
surroundings. In 1988, the first CA specifically designed for MRI,
a complex of gadolinium ion (Gd3+) and 1,4,7,10-tetraazacyclo-
dodecane-1,4,7,10 carboxylic acid (Gd–DOTA), became available
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for clinical use.4 Since then, many and varied CAs have been
developed to increase the sensitivity and specificity of detecting
and evaluating various pathologies. In CMR, CAs have played a key
role in a variety of applications such as perfusion,5 viability,6 tissue
characterisation,7 angiography8–10 and more recently molecular
imaging studies.11 Today, the CAs development continues to
evolve, bringing exciting opportunities for more sensitive and
targeted imaging to improve patient outcome, along with
associated challenges.
Many CAs developed are however limited to proof-of-concept
preclinical studies, and very few of them are currently approved
for human use. In our opinion, the major obstacles include
high dosages, toxicity, body clearance rate and long-term
immunogenicity. In this review, instead of a detailed description
of its history and clinical applications, we aim at critically
assessing recent developments of CA in the field of CMR, high-
lighting both benefits and drawbacks. An insight into challenges
facing the CAs’ development may promote coordinated eﬀort in
producing improved CMR agents and accelerating translation of
the development into clinical use.
2. Basics of tissue contrast in CMR
CMR scanners use strong magnetic fields, radiofrequency waves,
and field gradients to generate images of the heart. The radio-
frequency emission is tissue dependent which give rise to the
unparalleled ability of CMR to distinguish subtle diﬀerences in
the cardiovascular system. Briefly speaking, natural or intrinsic
tissue contrast is due to diﬀerence in the measured signals which
are majorly determined by four parameters in CMR: proton
density, T1, T2, and flow. Proton density presents its concentration
in tissue in the form of water and macromolecules (proteins, fat,
etc.). The T1 and T2 relaxation define the way that the excited
protons revert back to their equilibrium states. The eﬀect of flow
may be complex but the most common one is loss of signal from
rapidly flowing blood. CMR can produce tailored contrast for a
certain pathological condition by optimising these parameters
in a pulse sequence. We herein refer to Manning and Pennell’s
monograph12 for physics principles and a comprehensive
description of CMR.
Even though CMR has a high contrast sensitivity relative to
most other imaging modalities, the intrinsic tissue characteristics
can overlap for example between normal, reversibly and irreversibly
damaged heart. In this scenario, CAs can be used to enhance the
intrinsic characteristics within specific tissues or region of interest.
CAs for CMR can be classified according to various features
like the presence of a metal ion centre (usually Gd3+), the ability
to alter preferentially T1 or T2, their aﬃnity for CVS, their eﬀect
on image, or their chemical structures. As these features are
intimately related, a unique classification is unlikely.
The aﬃnity of a CA for CVS is probably themost known property
by the scientific community. We will use this feature to diﬀerentiate
CAs between conventional and molecular. Conventional CAs are
untargeted and passively absorbed in the damaged areas of CVS
whilst molecular CAs target specific biomolecules expressed in the
CVS during disease development.
Given the growing interest in CVDs at a molecular level, the
field of molecular CAs is rapidly emerging. The synergistic
combination of CMR and molecular imaging is expected to
provide a much better contrast of diseased CVS, providing
invaluable information on atherogenesis processes. Albeit on
its infancy, research in this field has been enormous and already
led to a plethora of targeted T1 and T2-based contrast reagents.
3. Developing eﬃcient contrast
agents: challenges and key factors
3.1 The balance between dosage and side eﬀects
Generally speaking, a good CA needs to aﬀord higher contrast
of diseased CVS, but with a dosage at which virtually no short
and long-term toxicity are encountered. Current CA dosage for
CMR can be up to 0.3 mmol kg1 M.13,14 Dosages over 0.3 mmol
kg1 may provide a further improvement, however, there is a
great concern over increased toxicity. Serious acute and chronic
eﬀects have been reported even at clinically approved dosage,
and a notorious example is the so-called Nephrogenic Systemic
Fibrosis (NSF).15,16 Additionally, a recent concern is the possible
adverse eﬀect of Gd accumulation in patients’ brains.17–19 The
clinical significance of this remains unclear, nevertheless in the
absence of sufficient evidence, the lowest possible dosage of
Gd-based CAs is highly recommended.
3.2 The chemical challenge
From a chemist’s perspective, the synthesis of more eﬃcient
CAs faces a great challenge: it must be simple, reliable, time
saving, high yielding, and scalable at least to kilogram scale.
Given the growing need of CAs for CMR, this challenge will
become more and more prominent in the future.
The recent merging molecular CMR also leads to the develop-
ment of the so-called targeted CAs. Compared to conventional CAs,
these agents are more specific by binding key biomolecules
expressed during CVDs to generate a better contrast. However,
synthesis of these agents is usually laborious and time consuming,
and low yields are usually encountered requiring novel protocols
and optimization. If such challenges are addressed, molecular
CMR can be implemented in a cost and time-eﬀective fashion,
representing a significant contribution alongside traditional CMR.
3.3 Key factors
When facing the aforementioned challenges, the researcher
must consider several key properties of a promising CA: its
ability to alter T1 and T2, body retention and clearance, side
eﬀects and the capability to accumulate preferentially in damaged
CVS. A typical example is Late Gadolinium Enhancement (LGE), a
well-known CMR protocol,20 which illustrates the importance of
these factors. LGE heavily relies on a passive accumulation of the
CA in damaged CVS, therefore a contrast medium with slow body
clearance will have a great impact in lowering the dose, minimising
side eﬀects and addressing the challenges mentioned in the
previous sections.21
Journal of Materials Chemistry B Review
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
4 
Ju
ly
 2
01
7.
 D
ow
nl
oa
de
d 
on
 2
2/
08
/2
01
7 
13
:4
8:
06
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2017 J. Mater. Chem. B, 2017, 5, 5714--5725 | 5717
3.4 The impact of molecular structure
The chemical structure of a CA is fundamental for understanding
its mode of action. By using the current CAs as a lead and the
Structure–Activity Relationship (SAR), synthetic and medicinal
chemists can predict and design improved CAs by tuning their
capability to alter T1 and T2, increase their stability
22 in the
bloodstream and improve specificity for damaged CVS. Chemists
can also design novel synthetic routes of promising CAs in a cost-
effective fashion. A clear example of SAR importance emerged in
the 1980s with the advent of the first generation of Gd-based CAs,
which will be described more in details in Section 4.1.1.
4. Conventional contrast reagents for
CMR
Conventional CAs can alter preferentially T1 or T2 and will be
described respectively in Sections 4.1 and 4.2. To note, CAs alter
both T1 and T2 of the water protons; however, such eﬀects are
usually more pronounced for either T1 or T2, and it is their
relative ratio that influence the categorization as either T1 or T2
based CAs.
4.1 T1-Based contrast agents: general remarks
T1-Based agents are the first class of CAs historically investigated
for CMR. These agents shorten the relaxation time of surrounding
water protons, and are called ‘‘positive’’ agents because they
produce image brightening in T1-weighted imaging sequences.
The paramagnetic Gd3+ has a high magnetic moment (m2 = 63
BM2) and is currently the metal ion of choice. However, free
Gd3+ is well-known to be cytotoxic and retained in liver, spleen
and bone.23–25 Due to its similarity with Ca2+ in atomic radius,
Gd3+ also binds ion channels and biomolecules like calmodulin
which mediates many crucial processes in the body such as
metabolism, apoptosis, smooth muscle contraction, short-long-
term memory and the immune response. To decrease its
toxicity, the Gd3+ needs to be held tightly by an organic ligand
to form stable complexes or chelates. Recent preclinical studies
showed that paramagnetic Mn2+-based CAs have also emerged
as safer alternatives and these are, potentially more compatible
with renally compromised patients.26
Conventional, T1-based CAs can be further divided into
extracellular, blood pool, multinuclear CAs. These are all
T1-based, but diﬀer in chemical structure, size and diﬀerent
number of Gd3+ per molecule.
4.1.1 Extracellular contrast agents. Extracellular CAs are
so-called as they are not internalised by the body cells. Upon
intravenous injection, these agents randomly distribute in
intravascular and interstitial spaces and are excreted rapidly
by the kidneys in their unchanged forms. Benefits include
simple and inexpensive synthesis, relatively low toxicity and
fast body clearance. The synthesis of these CAs involves chelation
of the Gd3+ with acyclic or macrocyclic multidentate ligands
containing multiple carboxylate anions (Fig. 1). The complexes
are kinetically and thermodynamically stable, resulting in the
minimal amount of free Gd3+ release in the body. The chemical
structure of the ligand plays a crucial role in the overall toxicity.27
CAs based on macrocyclic ligands (Gd–DOTA, Gd-DO3A butrol
and Gd-HP-DO3A) are more stable compared to their acyclic
counterparts based on Diethylene Triamine Pentaacetic Acid
(Gd-DTPA) because the so-called macrocyclic effect lead to a
lower release of free Gd3+ in the body.
Gd–DOTA showed enhancement on carotid vulnerable plaques
related to inflammatory process28,29 as well as Gd-DTPA30,31 and
Gd-DO3A-butrol,32 both at preclinical and clinical levels. Gd-DTPA
also afforded enhanced contrast in the coronary artery wall of
subjects after Acute Myocardium Infarction (AMI) compared to
normal subjects six days after infarction.33 Since the introduction
of Gd–DOTA in 1988, macrocyclic CAs have been extensively used
to enhance the signal in CMR scans for the last three decades.
These agents also image non-cardiovascular related diseases
like inflammatory edema and tumor angiogenesis.34 This may
lead to false diagnosis of CVD, which prompts further development
of CAs aimed specifically to damaged CVD.
4.1.2 Blood pool contrast agents. Blood pool is often
referred to as a blood deposit that occurs on walls and valves
of veins when they work ineﬀectively, thereby making it diﬃcult
for blood to return to the heart. Blood pool CAs are a valuable
solution compared to the first generation of CAs. These agents
are still extracellular and are specifically used for cardiovascular
applications. The T1-shortening capability in the damaged CVS
was initially thought to be the main reason for the improved
contrast. However, subsequent studies showed that such
enhancement is also due to a higher molecular size which
causes extended retention in the bloodstream; this results is a
preferential absorption and passive accumulation of the CAs
into atherosclerotic plaques via enhanced permeability and
retention eﬀect.35,36 This phenomenon is due to neovessels
formation in the endothelial lesions during the atherosclerotic
cascade. Given the growing importance of LGE in assessing
damaged myocardium,37 research and development of such
agents has been very intense. A recent example is gadofosveset
(MS-325)8,38 which is currently used in patients39 with carotid
artery stenosis for the detection of vulnerable plaque features.
The superior capability of generating enhanced contrast was
clearly demonstrated in a clinical trial, where LGE images
of chronic myocardial infarction was compared using both
MS-325 and Gd-DTPA. It was found that the accuracy of LGE
was higher than MS-325 54 minutes after contrast injection,
resulting in a sensitivity and specificity of 84% and 98%
respectively.40 Another promising example is gadofluorine
M,41 which aﬀords enhanced images in aortic42,43 and femoral
plaques of atherosclerotic rabbits.44 Independent studies45,46
demonstrated that upon injection in the bloodstream, gadofluorine
M self-assembles in small micelles that bind the albumin present in
Fig. 1 First generation of T1-based contrast agents used for CMR.
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the body, before penetrating into the atherosclerotic plaques; once
there it passively accumulates in the fibrous cap.
Recent studies demonstrated that also gadofosveset,9 Gd-B-
22956/147 and CB-Gd-DOTA-MA48 work via the same albumin-
binding mechanism. In particular, Gd-B-22956/1 has a high
aﬃnity to serum albumin and generates high contrast enhance-
ment in atherosclerotic plaques correlated with both neovessel
and macrophages density.49 An improved novel blood pool CA,
GdAAZTA-MADEC was recently developed and tested at a pre-
clinical model,50 aﬀording an enhanced contrast of damaged
CVS compared to gadofosveset and B25716/1 at 1 T. Herein, the
presence of a hydrophobic spacer between the deoxycholic acid
moiety and the Gd-AAZTA unit results in a stronger binding
with albumin, hence aﬀording a better contrast. Another pro-
mising contrast agent, P792, has been used for aortic arch and
carotid imaging and is on phase III clinical development.51,52
Gd-DTPA-BMA allowed enhanced imaging of both necrotic
core, calcification and loose matrix, all key components in
unstable plaques.53 A comparative study on the morphological
characterization of the carotid plaques has been carried out
with Gd-BOPTA54 and Gd-DTPA-BMA, and it was found that the
choice of the contrast agent has little impact.55 Other agents for
enhanced contrast of vascular tissues and plaques identification
are Gd-EOB-DTPA,56,57 Gd-Motexafin6 and Gd-AAZTA-C17.7
Fig. 2 shows some common blood pool CAs.
These findings suggest that chemists, clinicians and toxicologists
will need to use these CAs as a lead to develop novel systems. It is
anticipated that ligand design and synthesis will play a key role to
obtain the next generation of blood pool CAs by further altering T1
and increasing passive retention on damaged areas of CVS.58
So far, all CAs described herein have been designed to
provide a contrast which is optimal for the vast majority of
magnetic fields used in clinical CMR (up to 1.5 T). Higher
magnetic fields severely compromise image contrast as T1 is
reduced up to one-third compared to its maximum. This feature
could be a long term limitation, given the recent advents of high
field clinical scanners (3 T).
On the other hand, higher field MRI introduces serious
safety considerations: higher power radiofrequency pulses, potential
tissue heating, coil burns and, most prominently, the dangers
associated with a stronger magnetic field, such as ferromagnetic
materials and implanted medical devices in the patients, many of
which have not been evaluated at fields above 1.5 T.
Given these limitations there is still an enormous eﬀort to
develop alternative CAs to provide enhanced contrast with 1.5
T-based clinical scanners.
4.1.3 Multinuclear contrast agents. A recent and promising
solution are the so-called multinuclear CAs. Diﬀerent from the
aforementioned CAs, these agents contain more than one Gd3+
centre per molecule and have some advantages compared to their
mononuclear counterparts. Their higher molecular weight allows a
better retention in atherosclerotic plaques,59 whereas the presence
of multiple Gd3+ centers will be more eﬃcient in altering T1.
One of the most advanced CAs in clinical development is
Gadomer 1760 (Fig. 3, page 6), which is a dendritic chelate
carrying 24 Gd3+ centers.10,61,62
After intravenous injection Gadomer-17 distributes almost
exclusively within the intravascular space, providing enhanced
contrast of coronary arteries in patients with Coronary Artery
Disease (CAD)63 and in a swine model of myocardial perfusion.5
Another example is MPEG-polylysine-DTPA-Gd3 for an
enhanced vessel-muscle contrast where the half-life was shown
to be 14 h with a dose of 20 mmol of Gd per kg in preclinical
trials.64
Similar to blood pool CAs, the molecular size of multi-
nuclear CAs is too large for capillary extravasation, yet it is
small enough for rapid renal elimination, allowing improved
images of vessels and decreased toxicity compared to their
mononuclear counterparts. Polynuclear micelles containing
Gd-DOTAC16, Gd-DTPA-BSA or Gd-DO3A-OA (Fig. 4) have also
been prepared and gave enhanced images of macrophages in
plaques compared to standard mononuclear agents such as
Gd-DTPA.65,66 In another study high density lipoproteins (HDL)
containing Gd-DTPA-DMPE showed enhanced imaging of
atherosclerotic lesions.67–69
Whilst multinuclear CAs may allow enhanced images of
damaged CVS, they also pose serious issues due to potential
release of more free Gd3+ in liver, spleen and bones,70 requiring
longer and more expensive toxicology tests before their translation
Fig. 2 Most common blood pool contrast CAs for clinical and preclinical
CMR.
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into clinical uses. The use of biodegradable multinuclear CAs
can be a safer alternative. Preclinical studies showed that after
providing enhanced contrast of heart and blood vessels, endo-
genous enzymes in the body will degrade these CAs into lower
molecular weight fragments, which are more easily excreted by
the kidneys.71–74
4.2. T2-Based contrast agents
4.2.1 General remarks. T2-Based CAs mainly shorten the
transverse relaxation times of the surrounding water protons
and are termed ‘‘negative’’ agents because they produce darker
images in T2-weighted imaging sequences.
The ability of iron oxide nanoparticles to alter T2 relaxation
times in water was first discovered in 1978.75 Since then iron
oxide became the most common T2-based CA currently used.
Super Paramagnetic Iron Oxide Nanoparticles (SPIONS, diameter
size 50 to 300 nm) and Ultra-small SPIONS (USPIONS, diameter
size 15 to 30 nm) are iron oxide nanoparticles that can be coated
with dextran, silicates, or other non-immunogenic polymers for
preclinical and clinical applications. An advantage of SPIONS
over T1-based CAs is their transverse relaxivity which increases at
higher fields. This property suggests that SPIONS can be a
promising tool for the future, especially with the advent of high
field MRI. Additionally, unlike Gd-based CAs, SPIONS have
proven safe and are cleared as endogenous iron by the reticulo-
endothelial system.
There are many diﬀerent system containing SPIONS for
CVDs.76–79 The next sections will describe them separately, along
with recent advances, current challenges and future directions.
4.2.2 Non-specific contrast reagents: SPIONS. Non-specific
SPIONS are primarily addressed to macrophages which accumulate
in atherosclerotic lesions and promote the late stage formation of
atheroma and atherosclerotic plaques rupture.80
To date, ferumoxtran is one of the most extensively studied
CAs for imaging atherosclerotic plaques, both at preclinical and
clinical levels.81,82 Ferumoxtran oﬀers a number of advantages:
inexpensive synthesis, very good biocompatibility, high aﬃnity
for plaque macrophages and a low toxicity. It has been success-
fully applied to enhance images in stenotic carotid or atheromatous
plaques.81–83 In another study84 ferumoxtran has been administered
for CMR imaging of symptomatic patients scheduled for carotid
endarterectomy, showing enhanced contrast (up to 25%) and high
SPION content (up to 75%) in rupture-prone lesions, as confirmed
by histology. The optimal post-injection time for imaging sympto-
matic plaques was found to be between 24 and 36 h.81 The high
reliability of ferumoxtran has been used for therapy monitoring
in patients treated with different doses of atorvastatin.85,86
Another SPION based agent, Sinerem, also proved very promising
in providing enhanced images of macrophages in atherosclerotic
plaques of rabbits.87
Despite providing enhanced images of damaged CVS, these
CAs lack of tissue specificity. Ferumoxtran is a polysaccharide-
coated SPION and can be easily internalized by the macro-
phages present in other tissues of the body, in particular by the
Kupﬀer cells in the liver.88 Synthetic challenges also arise from
controlling the size of the SPIONs, a key factor. Studies showed
that smaller nanoparticles (up to 5 nm) would be more advan-
tageous for easier body clearance and decreased toxicity.89–91
Phagocytic cells internalize large particles more effectively,
whereas nonphagocytic T cells internalize intermediate-sized
particles more efficiently.92–94
To increase the CVS specificity, many research groups
investigated diﬀerent sizes of SPIONS and polymer-coating
chemicals. Mannan95 coated SPIONS allowed enhanced images
of atherosclerotic walls in rabbits,96 whereas citrate97 and Dextran
Sulphate (DS) coated SPIONS provided enhanced contrast of
atherosclerotic plaques both in preclinical and clinical studies.98
5. Molecular imaging of CVDs: the
emerging role of molecular contrast
reagents
5.1 General remarks
Molecular imaging is able to visualize specific biomolecules
expressed during a broad range of pathologies. This technique
Fig. 3 Structures of Gadomer 17 and MPEG polylysine DTPA polymers.
Fig. 4 Multinuclear contrast agents currently developed for CMR.
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has been increasingly applied to detect CVDs as many biomolecules
are expressed de novo during inflammation and endothelial dys-
function. The most important biomolecules known so far are E and
P-selectins, integrins, Vascular Cell Adhesion Molecule 1 (VCAM-1),
Intercellular Adhesion Molecule 1 (ICAM-1), peroxidases and Matrix
Metalloproteinases (MMPs). These molecules promote leukocyte
rolling and adhesion on the wall of the inflamed endothelium
and their subsequent transmigration into the sub-endothelial space,
all important events in the development of CVDs (Fig. 5).99–101
Integrin avb3 promotes leucocyte extravasation through the
extracellular matrix and is heavily involved in atherosclerosis
progression and in restenosis. MMPs are a broad family of
endopeptidases involved in rupture-prone plaques and play a
key role in the degradation and remodelling of the extracellular
matrix. Myeloperoxidases (MPO) promote oxidation of low-density
lipoprotein (LDL).102 Fibrin is also an important component
of atherosclerotic plaques and is present in advanced lesions,
whereas elastin is important in vascular remodelling. Low-
density Lipoprotein Receptor-1 (LOX-1) triggers inflammation
in the endothelium and is expressed in vulnerable plaques.
5.2 Molecular T1-based contrast agents
Targeted T1-based CAs are made by linking three components:
the first one is a targeting vector which binds the biomolecule
of interest, the second one is a clinical T1 based CA which
provides the contrast, and the third one is a linker which holds
the first two components together.103 The chemical process
aimed to link these components together is called bioconjugation,
which generally results in the formation of biologically stable
molecular moieties like amides, ethers or thioesters. The
enhanced contrast of these CAs derives from both T1 alteration
and the specificity of the CA for the biomolecule of interest
(Fig. 6). The mode of action is diﬀerent from the conventional
CAs (described in Section 4) which are not targeted to any
molecule but accumulate passively in the damaged CVS.
Compared to conventional CAs, molecular CAs oﬀer many
advantages: better specificity, improved contrast and a better
understanding of molecular processes behind CVDs. Clinicians
and medicinal chemists will use these advantages to develop
better drugs and improved therapies. Long term advantages are
also detection of CVDs at subclinical levels, identification of
in vivo markers for stable and unstable plaques and patient-
individualised risk assessment.
Despite the great promise, many challenges still hamper the
translation of molecular CAs into clinical use: complex multi-
step syntheses and optimisation processes are often needed.
To obtain the best contrast, bioconjugation must not alter the
aﬃnity of the vector for the targeted biomolecule or decrease
the probe capability to alter T1. In case of Gd-based molecular
CAs, bioconjugation may also lead to the release of free Gd
in the body, requiring longer and more expensive toxicology
studies.
Given these challenges, research in this field has been very
intense and there is a plethora of systems already reported,
examples include E and P-selectin imaging with Gd-F-P717,
Gd-P717104–107 and Gd-DTPA-BsLexA, respectively.108,109 A targeted
Gd-based contrast agent was used to image MMPs activation110
as well as fibrin111–113 with Gd EP-2104R114 and EP-1242.115
Gd-LMI1174116 and BMS753951117 allowed enhanced images of
plaques by targeting elastin and has been used to quantify the
changes in elastin content in plaques regression in a mouse
model of atherosclerosis. Targeted liposomes containing
Gd-DTPA successfully imaged low density lipoprotein receptors
in ApoE(/) mice.118,119
Fig. 5 The beginning of atherosclerosis. Following an inflammatory
response, E and P selectins are expressed and translocated on the
endothelial surface, causing leucocytes in the blood stream (blue) to
tether, roll and accumulate on the endothelium, triggering the formation
of atherosclerotic plaques.
Fig. 6 Some T1-based targeted contrast agents currently in preclinical
development.
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Gd-DTPA-G-R826 is a conjugate containing the peptide
sequence LIKKPF: this agent binds the phosphatidylserine
receptor of apoptotic macrophages, allowing enhanced images
of atherosclerotic plaques.120 A similar peptide-based agent has
been reported to image plaque progression.121
Another group developed a Gd-DTPA-mim-RGD agent that
allowed enhanced images of inflamed blood vessels by targeting
integrin avb3 in vulnerable atherosclerotic plaques. The authors
also reported a decreased contrast when the analogue, non-
targeted Gd-DTPA was used in the same model.122
Contrast agents containing amphiphilic fullerenes C60,
123
C70
124 have also been recently developed, providing enhanced
visualization of specific receptors on foam cells in atherosclerotic
plaques compared to mononuclear Gd–DOTA.125
In a similar fashion, Gd-DTPA-MPO provided enhanced
contrast by targeting myeloperoxidase activity in mice.126 Finally,
P947 is a Gd–DOTA derived agent that afforded enhanced images
by targeting the MMPs that accumulate in atherosclerotic
lesions.127,128 Fig. 6 shows some promising CAs for targeted CMR.
5.3 Molecular T2-based contrast agents
Similar to what has been discussed for T1-based molecular CAs,
SPIONS can be targeted to specific biomolecules involved in
CVDs. This can be achieved by synthetically modifying the SPIONS
coating to allow attachment of targeting vectors. The resulting CAs
oﬀer enhanced images of CVS, improved bioavailability and lower
toxicity. All these features can facilitate the translation of these
systems into clinical use.
The synthetic challenges described in Section 5.2 also apply
for molecular T2-based CAs. For these CAs, bioconjugation and
formulation constitute even more critical steps as they may
cause self-aggregation and precipitation of insoluble CAs both
in vitro and in vivo. As nanoparticle-based CAs translate into the
clinic, one additional challenge is to maximize the value-to-cost
ratio for high volume product scale-up.
Research in this field has been intense, recent examples
(Table 1) are contrast agent VINP-28, a peptide-bound nano-
particle with high aﬃnity for VCAM-1 that aﬀorded enhanced
contrast in the aortic root of ApoE/ mice 48 hours after
injection.129 The contrast obtained with VINP-28 has been also
used for therapy monitoring where the enhanced signal in
atherosclerotic plaques strongly decreased after an 8 week
treatment with Statin. Further examples of VCAM-1 targeted
imaging with SPIONS have been published.130,131
SPIONS have also been conjugated with antibodies and with
a SLex mimics133,134 to detect E-selectins and CD44, both cell-
adhesionmolecules involved in the early stages of atherosclerosis
and in the formation of atherosclerotic plaques.135 In another
study, SPIONS were conjugated with fumagillin, an endothelium
selective anti-angiogenic drug. The developed agent oﬀers
enhanced contrast via targeting integrin avb3 in early endothelial
inflammation,136 with promising therapeutic applications.137
6. Conclusions
Since the introduction of Gd–DOTA in 1988 there has been a
large repertoire of CAs currently available for both preclinical
and clinical CMR. However, they offer both advantages and
disadvantages.
The first generation of T1-based CAs aﬀords enhanced images
of CVS and is straightforward to synthesize. However higher
dosages may be required in order to increase CMR sensitivity,
which also increases the toxicity due to the release of more free
Gd3+ into the body. Blood pool and multinuclear CAs recently
emerged as a better option to obtain enhanced contrast of
damaged CVS, however their synthesis is less straightforward
especially in the case of multinuclear CAs. Nanoparticles hold a
promising future in CMR. However, a major limitation is the long
post-injection time (24 to 48 hours) which is sometimes needed
to obtain an enhanced contrast of CVS. To date, unaddressed
challenges include method reproducibility upon scale up syntheses
and size control.
Targeted T1 and T2-based CAs hold a great promise for the
future of CMR. Distinct from conventional non-targeted CAs,
these agents are invaluable in enhancing our understanding of
CVDs at molecular level, and helping clinicians to detect
cardiovascular abnormalities at subclinical stages. However,
both design and synthesis of such agents can be much more
complex and expensive.
Last but not the least, it is anticipated that the role of
medicinal and synthetic chemists in this field will become
more and more important in the future, as the developers have
to face all the challenges encountered with design, synthesis,
analysis, preclinical and clinical evaluations of these chemical
agents.
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